Literature DB >> 6861863

Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

M Stäubli, J Bircher, R L Galeazzi, H Remund, H Studer.   

Abstract

In 17 patients on long term therapy with amiodarone, serum drug levels measured by HPLC were related to pharmacological effects. At steady state, serum levels were directly proportional to the dose, 5 mg/kg per day leading to an average serum level of approximately 2.5 mumol/l. The non-amiodarone level of iodine averaged 4-times higher than the level of amiodarone iodine. The elimination half-life of amiodarone ranged from 21 to 78 days, and of non-amiodarone iodine from 24 to 160 days. Control of arrhythmias was satisfactory in all 12 evaluable patients, when the serum amiodarone level exceeded 1.5 mumol/l. Deterioration of vision and polyserositis occurred only at amiodarone levels above 4 mumol/l. Tentatively, a therapeutic range of 1.5 to 4 mumol/l is proposed. In contrast, thyroid dysfunction was observed at any amiodarone level. In view of the narrow therapeutic window, therapy with amiodarone may be optimized by monitoring its serum level and in addition, thyroid function should be regularly checked.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861863     DOI: 10.1007/bf00609891

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone.

Authors:  M H Jonckheer; P Blockx; R Kaivers; G Wyffels
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

2.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.

Authors:  M B Rosenbaum; P A Chiale; D Ryba; M V Elizari
Journal:  Am J Cardiol       Date:  1974-08       Impact factor: 2.778

3.  Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment.

Authors:  W J McKenna; L Harris; G Perez; D M Krikler; C Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1981-08

4.  Prednisone in amiodarone-induced thyrotoxicosis.

Authors:  C Wimpfheimer; M Stäubli; J Schädelin; H Studer
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-19

5.  Effect of amiodarone in the Wolff-Parkinson-White syndrome.

Authors:  H J Wellens; K I Lie; F W Bär; J C Wesdorp; H J Dohmen; D R Düren; D Durrer
Journal:  Am J Cardiol       Date:  1976-08       Impact factor: 2.778

6.  Amiodarone-induced thyrotoxicosis: four cases and a review of the literature.

Authors:  S Keidar; E Grenadier; A Palant
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

7.  Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases.

Authors:  P Coumel; J Fidelle
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

8.  Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.

Authors:  A Burger; D Dinichert; P Nicod; M Jenny; T Lemarchand-Béraud; M B Vallotton
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

9.  Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy.

Authors:  K Nademanee; B N Singh; J A Hendrickson; A W Reed; S Melmed; J Hershman
Journal:  Circulation       Date:  1982-07       Impact factor: 29.690

10.  Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration.

Authors:  S Melmed; K Nademanee; A W Reed; J A Hendrickson; B N Singh; J M Hershman
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

View more
  27 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Stability of plasma amiodarone levels during chronic oral therapy.

Authors:  K Robinson; A Johnston; S Walker; J Mulrow; D Holt; W McKenna
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 3.  Amiodarone therapeutic plasma concentration monitoring. Is it practical?

Authors:  T Maling
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

4.  Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole.

Authors:  O Van Reeth; C Decoster; J Unger
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Does amiodarone affect heart rate by inhibiting the intracellular generation of triiodothyronine from thyroxine?

Authors:  M Lindenmeyer; S Spörri; M Stäubli; A Studer; H Studer
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

6.  The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Authors:  M Arboix; M E Frati; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Amiodarone induced optic neuropathy.

Authors:  P K Nagra; R Foroozan; P J Savino; I Castillo; R C Sergott
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 8.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

10.  Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

Authors:  M Pirovino; U Honegger; O Müller; T Zysset; A Küpfer; M Tinel; D Pessayre
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.